1.Validity and reliability of the Chinese version of the Kutcher Adolescent Depression Scale
Huiming ZHOU ; Nan HAO ; Yasong DU ; Yanyu LIU ; Yutong SUI ; Yanhua WANG ; Yanan CUI ; Qiuping ZHONG ; Xiujuan JIAO ; Yifeng WEI ; Stanley KUTCHER
Chinese Mental Health Journal 2015;(6):413-418
Objective:To assess the validity and reliability of the Chinese version of the eleven-item Kutcher Adolescent Depression Scale (KADS-11)in Chinese adolescents,calculate its optimal cut-off value and the sensi-tivity and specificity,and explore the possibility of providing a useful tool to assess the severity of adolescent de-pressive symptoms.Methods:Totally 3180 students aged 11 -17 years were selected from schools in 6 provinces and Shanghai.All of them were asked to complete the KADS-11 and Children Depression Inventory (CDI). Students whose CDI scores were above 19 (including 19)were diagnosed with the DSM-IV criteria of depressive disorder,73 students from Shanghai sample were assessed with KADS-11 and CDI to analyze the test-retest reliabil-ity 1 month later.Results:Exploratory factor analysis showed that KADS-11 had 2 factors,and confirmatory factor analysis tested proved the 2-factor model fit better than the one-factor model.The KADS-11 total scores were posi-tively correlated with CDI total scores (r =0.74,P <0.01 ),and the KADS-11 scores were higher in depressive group than those in non-depressive group.The mean area under the curve (AUC)of KADS-11was 0.94,the mean area under the curve of each item ranged from 0.7 to 0.9.The optimal cut-off point of KADS-11 was total score≥9,sensitivity and specificity were 89% and 90% respectively.The Cronbach's alpha coefficient of the KADS-11 was 0.84,the spilt-half reliability coefficient was 0.71 (P <0.01),and the test-retest coefficient was 0.77 (P <0.01).Conclusion:The KADS-11 is appropriate for Chinese adolescents because of its good validity,reliability and diagnosis accuracy,it could be used to assess depressive symptoms for adolescents.
2.Herbal textual research on Bunge pricklyash seed
Yutong DUAN ; Junhan YANG ; Ming RAN ; Jiaxin SUI ; Lingjie MENG ; Wanping SUN
China Pharmacist 2024;27(2):357-364
By consulting the relevant literature and historical herbal literature,the name,origin and harvesting,efficacy and indications,as well as nature,taste,and meridians of Bunge pricklyash seed were reviewed."Jiaomu"as a medicinal herb name was first recorded in the"Compendium of Materia Medica Annotations",and later generations also used"Jiaomu"as a proper name.Bunge pricklyash seeds are the seeds of the Rutaceae plant Sichuan Bunge pricklyash seed or green Bunge pricklyash seed.They are harvested when they mature in autumn from August to October,and can be processed by net,stir-frying or salt.It can promote diuresis and reduce swelling,treat kidney deficiency and tinnitus,and is mainly used to treat bloating in the abdomen.It is non-toxic or slightly toxic.This article traced the origin of Bunge pricklyash seed,studied the history of medicine,clarified the original traditional Chinese medicine properties of Bunge pricklyash seed,and provided scientific basis for the correct clinical use and the national formulation of quality standards for this herb.
3.Mechanism of NF-κB Signaling Pathway in Regulating Lung Cancer and Intervention of Traditional Chinese Medicine: A Review
Xue GENG ; Wencheng CHI ; Xiaoyue LIN ; Yutong SUI ; Hua LIANG ; Jiakang JIANG
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(16):207-216
Lung cancer is the leading cause of cancer-related deaths, and standard treatments for lung cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, have shown significant clinical effects. However, current available treatment strategies are still unable to cure the disease. Since the majority of lung cancer patients are diagnosed at an advanced stage, surgical options are often lost, and the primary approach is typically a combination of radiotherapy and chemotherapy. However, the adverse reactions associated with these treatments limit their effectiveness and application, and the damage caused to normal tissues is often more severe than that inflicted on the tumor. Currently, traditional Chinese medicine (TCM) has been used as part of combination therapy for cancer treatment due to its unique system of syndrome differentiation, flexible compatibility, and safety and efficacy. TCM prescriptions and single drugs with multiple components and targets can simultaneously regulate multiple pathways. As reported, among numerous pathways involved in the regulation of lung cancer, the nuclear factor-κB (NF-κB) signaling pathway plays a key role in inducing cell transcription and is one of the main pathways involved in the occurrence and development of lung cancer. It can specifically regulate inflammatory responses, cell proliferation, apoptosis, invasion and metastasis, angiogenesis, and multidrug resistance in lung cancer. TCM prescriptions and single drugs can inhibit lung cancer cell proliferation, invasion, and metastasis, induce apoptosis and autophagy in lung cancer cells, suppress angiogenesis, regulate immune function, and treat multidrug resistance by regulating the NF-κB signaling pathway. Therefore, they play a role in intervening in lung cancer. However, there is currently a lack of systematic literature research that comprehensively summarizes and elucidates these aspects in China and abroad. Therefore, it is important to provide a systematic elucidation of the mechanism underlying the regulation of the NF-κB signaling pathway in lung cancer and review TCM interventions in lung cancer based on the NF-κB signaling pathway. This study is expected to provide references for the clinical application of lung cancer therapeutic drugs and the development of new drugs.
4.Chinese expert consensus on diagnosis, treatment and prevention of venous thrombus embolism associated with chest trauma (2022 version)
Kaibin LIU ; Yi YANG ; Hui LI ; Yonten TSRING ; Zhiming CHEN ; Hao CHEN ; Xinglong FAN ; Congrong GAO ; Chundong GU ; Yutong GU ; Guangwei GUO ; Zhanlin GUO ; Jian HU ; Ping HU ; Hai HUANG ; Lijun HUANG ; Weiwei HE ; Longyu JIN ; Baoli JING ; Zhigang LIANG ; Feng LIN ; Wenpan LIU ; Danqing LI ; Xiaoliang LI ; Zhenyu LI ; Haitao MA ; Guibin QIAO ; Zheng RUAN ; Gang SUI ; Dongbin WANG ; Mingsong WANG ; Lei XUE ; Fei XIA ; Enwu XU ; Quan XU ; Jun YI ; Yunfeng YI ; Jianguo ZHANG ; Dongsheng ZHANG ; Qiang ZHANG ; Zhiming ZHOU ; Zhiqiang ZOU
Chinese Journal of Trauma 2022;38(7):581-591
Chest trauma is one of the most common injuries. Venous thromboembolism (VTE) as a common complication of chest trauma seriously affects the quality of patients′ life and even leads to death. Although there are some consensus and guidelines on the prevention and treatment of VTE at home and abroad, the current literatures lack specificity considering the diagnosis, treatment and prevention of VTE in patients with chest trauma have their own characteristics, especially for those with blunt trauma. Accordingly, China Chest Injury Research Society and editorial board of Chinese Journal of Traumatology organized relevant domestic experts to jointly formulate the Chinese expert consensus on the diagnosis, treatment and prevention of chest trauma venous thromboembolism associated with chest trauma (2022 version). This consensus provides expert recommendations of different levels as academic guidance in terms of the characteristics, clinical manifestations, risk assessment, diagnosis, treatment, and prevention of chest trauma-related VTE, so as to offer a reference for clinical application.